通化東寶(600867.SH)獲甘精胰島素注射液《藥品註冊批件》
格隆匯12月11日丨通化東寶(600867.SH)公佈,公司近日收到國家藥品監督管理局核准簽發的甘精胰島素注射液《藥品註冊批件》,截至本公告日,公司在該項目中已投入研發費用人民幣約7181萬元。
甘精胰島素及其注射液是一種新型的胰島素類似物,具有長效、血藥濃度無峯值、平穩地降低患者血糖的作用。法國賽諾菲安萬特公司是其原研生產廠家,商品名為來得時®(lantus)。分別於2000年4月和6月由美國食品藥品管理局(FDA)和歐洲醫藥產品評審委員會批准用於治療1型和2型糖尿病。2004年來得時®在中國上市。該產品上市以來,憑藉其良好的療效,迅速成為國際上胰島素及其類似物中最耀眼的明星,連續多年銷售排行榜中位列同類產品中的第一位。國內企業目前已有兩家公司獲得甘精胰島素注射液的上市許可,分別是甘李藥業股份有限公司和珠海聯邦制藥股份有限公司,他們分別於2005和2017年獲得國家食品藥品監督管理總局頒發的生產批件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.